Evolve Private Wealth LLC Takes $1.39 Million Position in Medpace Holdings, Inc. $MEDP

Evolve Private Wealth LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,618 shares of the company’s stock, valued at approximately $1,386,000.

A number of other institutional investors also recently modified their holdings of MEDP. BOKF NA increased its position in Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares in the last quarter. UMB Bank n.a. boosted its position in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after buying an additional 24 shares in the last quarter. Schulhoff & Co. Inc. increased its holdings in shares of Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC increased its holdings in shares of Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after buying an additional 26 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $620.75 on Monday. The business has a 50-day moving average price of $550.16 and a two-hundred day moving average price of $492.03. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market cap of $17.33 billion, a P/E ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the company posted $3.10 earnings per share. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at $2,302,157.70. The trade was a 65.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 122,261 shares of company stock worth $71,729,129 over the last ninety days. 20.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MEDP. Royal Bank Of Canada raised their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.